Search results
Results from the WOW.Com Content Network
Technetium (99m Tc) sestamibi (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile ( MIBI ) ligands .
Myocardial perfusion imaging or scanning (also referred to as MPI or MPS) is a nuclear medicine procedure that illustrates the function of the heart muscle (). [1]It evaluates many heart conditions, such as coronary artery disease (CAD), [2] hypertrophic cardiomyopathy and heart wall motion abnormalities.
Perfusion stress test (with 99mTc labelled sestamibi [15]) is appropriate for select patients, especially those with an abnormal resting electrocardiogram. Intracoronary ultrasound or angiogram can provide more information but is invasive and carries the risk of complications associated with cardiac catheterization procedures.
These employ the same radioligands and have the same uses as SPECT scanning, but are able to provide even finer 3-D localization of high-uptake tissues, in cases where finer resolution is needed. An example is the sestamibi parathyroid scan which is performed using the 99m Tc radioligand sestamibi, and can be done in either SPECT or SPECT/CT ...
Most of the data on bank "stress tests" has already been leaked to the press, which could prompt an investigation into why such sensitive information about public companies was disclosed early.
The underlying principle is that under conditions of stress, diseased myocardium receives less blood flow than normal myocardium. MPI is one of several types of cardiac stress test . A cardiac specific radiopharmaceutical is administered, e.g., 99m Tc- tetrofosmin (Myoview, GE healthcare), 99m Tc-sestamibi (Cardiolite, Bristol-Myers Squibb) or ...
High-stress lifestyle. utah778/Istockphoto. Diagnosing. The diagnostic process for atherosclerosis often starts by visiting your primary healthcare provider. If you’re diagnosed with ...
Novo Nordisk said it expects results from a second Phase 3 trial of the medicine, this one in people with type 2 diabetes, in the first half of 2025. The study reported Friday, which Novo Nordisk ...